The new dedicated facility will be responsible for the manufacturing of the company’s complete TWO2 therapy product range, including all the devices and associated consumables.

AOTI has maintained a strong manufacturing presence in Galway, Ireland since 2007 when it first formed its manufacturing subsidiary, AOTI.

AOTI president and CEO Dr Mike Griffiths said: “We are delighted to invest in this new facility that will allow us to more effectively ramp up production of our unique multi-modality wound care therapy product line to meet our continually expanding supply needs.”

AOTI is experiencing extensive growth in the demand for its products as further high level clinical evidence is published as to TWO2 therapy efficacy and cost effectiveness, which is expected to lead to broader reimbursement being established across more market segments both in the USA and Internationally.

This growth is expected to continue exponentially and is fueling expansion of not only the company’s sales and support infrastructure, but also its logistics, administrative and manufacturing capabilities.

AOTI chief financial officer Anthony Moffatt said: “Like so many other leading medical device companies, we recognize the combined benefits that Ireland offers; with a highly skilled workforce and very attractive tax structure, making it the ideal location within the European Union to expand.”

AOTI also announced today the hiring of Rene Cortes as its new head of Sales Marketing and Training for the USA. Rene joins the company with 25 years of medical device sales, marketing and training experience across a broad range of companies, most recently at the leading innovative patient monitoring company, Masimo.

AOTI Inc. is a private company based in Oceanside, California USA and Galway, Ireland, that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses.

Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is unsurpassed in fully closing Diabetic, Venous and Pressure ulcers alike.

Source: Company Press Release